This self-protein is associated with human breast and ovarian cancers and other adenocarcinomas including some lung and prostate tumors. The study included 64 patients, all of whom prior to the study had completed treatment for Stage III or IV breast, ovarian and lung cancer and had undergone treatment to the point of maximal response. A quarter of the patients were followed for the persistence of immune response after a series of immunizations was completed. Approximately 50 percent of the patients remaining in follow-up have persistent detectable immunity up to two years after the completion of the study. Our group, as well as groups working with other tumor antigen systems, has shown that measurable tumor-specific immune responses can be generated by vaccinating cancer patients.
Safety is a foremost concern.
The U.S. Army Medical Research and Material Command supports this, and other breast cancer research, through congressional funding for the eradication of breast cancer. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary vaccine components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals and diagnostics targeting products that are Powered by Corixa TM technology with the goal of making its potential products available to patients around the world. About Immunex Immunex Corporation is a biopharmaceutical company dedicated to improving lives through immune system science innovations.